Patients, doctors await FDA decision on experimental Alzheimer’s drug

January 6, 2023

Lecanemab: It’s an experimental medication that’s been shown in trials to slow cognitive decline in people with Alzheimer’s disease.

Endolymphatic hydrops tied to hearing loss severity in Meniere disease
For patients with bilateral Meniere disease (MD), features of endolymphatic hydrops correlate with the severity of hearing loss and staging of MD, according to a study published online Sept. 16 in Head & Face Medicine.
Study identifies potential novel drug to treat tuberculosis
A new study published in Microbiology Spectrum demonstrates that a novel semi-synthetic compound can be derived from natural compounds to produce potent activity against Mycobacterium tuberculosis, including multi-drug resistant strains. The new compound provides a promising chemical scaffold to develop new potent anti-tuberculosis drugs.
Research shows the prevalence of mental disorders is higher in transgender, gender-diverse people
There is a higher prevalence of mental disorders and suicidal behavior among transgender and gender-diverse (TGD) people versus the cisgender population, according to a research letter published online Oct. 2 in JAMA Network Open.
Eli Lilly weight-loss drug copycats dealt blow as shortage ends
Eli Lilly & Co.'s blockbuster weight-loss and diabetes drugs are no longer considered to be in shortage in the US, threatening to upend the many knockoffs that became popular when patients couldn't find the brand-name medicines.
Study highlights the relationship between governance and vaccine coverage
A study by doctoral student Raoul Kamadjeu and Associate Professors Katarzyna Wyka and Elizabeth Kelvin suggests that strengthening governance structures and processes could have significant positive impacts on immunization programs and public health in general. The study is published in the journal Vaccine.

Patients, doctors await FDA decision on experimental Alzheimer’s drug

Recent Posts

JUST IN